The FDA approved Eli Lilly's obesity drug Foundayo (orforglipron) for adults with obesity or those overweight with weight-related conditions. Shares of Eli Lilly rose more than 5% on the approval, signaling a material positive boost to the company's commercial prospects and investor sentiment.
The FDA approved Eli Lilly's obesity drug Foundayo (orforglipron) for adults with obesity or those overweight with weight-related conditions. Shares of Eli Lilly rose more than 5% on the approval, signaling a material positive boost to the company's commercial prospects and investor sentiment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
